Valérie Siroux1, Anne Boudier2, Maïa Dolgopoloff2, Sébastien Chanoine2, Jean Bousquet3, Frederic Gormand4, Jocelyne Just5, Nicole Le Moual6, Rachel Nadif6, Christophe Pison7, Raphaëlle Varraso6, Regis Matran8, Isabelle Pin2. 1. Université Grenoble Alpes, IAB, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Grenoble, France; Inserm, IAB, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Grenoble, France; CHU de Grenoble, IAB, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Grenoble, France. Electronic address: Valerie.siroux@ujf-grenoble.fr. 2. Université Grenoble Alpes, IAB, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Grenoble, France; Inserm, IAB, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Grenoble, France; CHU de Grenoble, IAB, Team of Environmental Epidemiology applied to Reproduction and Respiratory Health, Grenoble, France. 3. Inserm U1168, VIMA (Aging and chronic diseases, Epidemiological and public health approaches), Villejuif, France; Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny-le-Bretonneux, France; University Hospital, Montpellier, and MeDALL (Mechanisms of the Development of Allergy, FP7), Montpellier, France. 4. CHU de Lyon, Pneumology Department, Lyon, France. 5. Assistance Publique-Hôpitaux de Paris, Hôpital Armand-Trousseau, Allergology Department, Paris, France; Université Paris 6 Pierre et Marie Curie, Paris, France. 6. Inserm U1168, VIMA (Aging and chronic diseases, Epidemiological and public health approaches), Villejuif, France; Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny-le-Bretonneux, France. 7. Clinique Universitaire de Pneumologie, Pôle de Cancérologie, Médecine Aiguë et Communautaire, CHU Grenoble, Grenoble, France; Inserm 1055, Grenoble, France; Universite Joseph Fourier, Grenoble, France. 8. Université Lille Nord de France, Lille, France.
Abstract
BACKGROUND: Whether small-airway obstruction contributes to the long-term evolution of asthma remains unknown. OBJECTIVES: Our aim was to assess whether the level of forced midexpiratory flow between 25% and 75% of forced vital capacity (FEF25-75) was associated with the persistence of current asthma over 20 years and the subsequent risk for uncontrolled asthma independently of FEV1. METHODS: We studied 337 participants (142 children and 225 adults) with current asthma (asthma attacks or treatment in the past 12 months) recruited to the Epidemiological Study on the Genetics and Environment of Asthma (EGEA1) and followed up at the 12- and 20-year surveys. Persistent current asthma was defined by current asthma reported at each survey. A lung function test and a methacholine challenge test were performed at EGEA1 and EGEA2. Adjusted odds ratios (ORs) were estimated for FEF25-75 decreased by 10% of predicted value. RESULTS: A reduced level of FEF25-75 at EGEA1 increased the risk of long-term asthma persistence (adjusted OR, 1.14; 95% CI, 1.00-1.29). In children the association remained significant after further adjustment for FEV1 and in participants with FEV1 of greater than 80% of predicted value. A reduced FEF25-75 level at EGEA1 was significantly associated with more severe bronchial hyperresponsiveness (P < .0001) and with current asthma a decade later, with an association that tended to be stronger in those with (adjusted OR, 1.44; 95% CI, 1.14-1.81) compared with those without (adjusted OR, 1.21; 95% CI, 1.05-1.41) asthma exacerbation. CONCLUSION: Our analysis is the first to suggest that small-airway obstruction, as assessed based on FEF25-75, might contribute to the long-term persistence of asthma and the subsequent risk for poor asthma outcomes independently from effects of the large airways.
BACKGROUND: Whether small-airway obstruction contributes to the long-term evolution of asthma remains unknown. OBJECTIVES: Our aim was to assess whether the level of forced midexpiratory flow between 25% and 75% of forced vital capacity (FEF25-75) was associated with the persistence of current asthma over 20 years and the subsequent risk for uncontrolled asthma independently of FEV1. METHODS: We studied 337 participants (142 children and 225 adults) with current asthma (asthma attacks or treatment in the past 12 months) recruited to the Epidemiological Study on the Genetics and Environment of Asthma (EGEA1) and followed up at the 12- and 20-year surveys. Persistent current asthma was defined by current asthma reported at each survey. A lung function test and a methacholine challenge test were performed at EGEA1 and EGEA2. Adjusted odds ratios (ORs) were estimated for FEF25-75 decreased by 10% of predicted value. RESULTS: A reduced level of FEF25-75 at EGEA1 increased the risk of long-term asthma persistence (adjusted OR, 1.14; 95% CI, 1.00-1.29). In children the association remained significant after further adjustment for FEV1 and in participants with FEV1 of greater than 80% of predicted value. A reduced FEF25-75 level at EGEA1 was significantly associated with more severe bronchial hyperresponsiveness (P < .0001) and with current asthma a decade later, with an association that tended to be stronger in those with (adjusted OR, 1.44; 95% CI, 1.14-1.81) compared with those without (adjusted OR, 1.21; 95% CI, 1.05-1.41) asthma exacerbation. CONCLUSION: Our analysis is the first to suggest that small-airway obstruction, as assessed based on FEF25-75, might contribute to the long-term persistence of asthma and the subsequent risk for poor asthma outcomes independently from effects of the large airways.
Authors: Stanley P Galant; Hirsh D Komarow; Hye-Won Shin; Salman Siddiqui; Brian J Lipworth Journal: Ann Allergy Asthma Immunol Date: 2017-06 Impact factor: 6.347
Authors: Mônica Versiani Nunes Pinheiro de Queiroz; Cristina Gonçalves Alvim; Álvaro A Cruz; Laura Maria de Lima Belizário Facury Lasmar Journal: Clin Transl Allergy Date: 2017-12-15 Impact factor: 5.871
Authors: Amelia Licari; Ilaria Brambilla; Alessia Marseglia; Maria De Filippo; Valeria Paganelli; Gian L Marseglia Journal: Front Pediatr Date: 2018-06-19 Impact factor: 3.418
Authors: Jouni J K Jaakkola; Samu Hernberg; Taina K Lajunen; Penpatra Sripaijboonkij; L Pekka Malmberg; Maritta S Jaakkola Journal: BMJ Open Respir Res Date: 2019-03-25